Andrew Breitbart’s heart was too big to fail, but it did anyway.

By keeping the focus on better health for real people, perhaps we’ll develop both the humility to recognize how little we still understand as well as the drive to ensure — and emphatically demand — that our advances ultimately wind up not only in papers, but also in patients.

Grand claims about the transformative power of technology in education are common, yet decades of high school redesign have yielded mixed results. One of the most widely touted efforts to tackle these challenges has been the School of the Future in the Philadelphia School District, created in 2006 through a...

If education philanthropists want to influence policy, then they must open themselves to more public debate about their  plans and goals.

The one thing on which our political leaders seem to agree is the need for corporate tax reform. But amid all of the promising rhetoric there is significant cause for concern. Many proposals, particularly those of Messrs. Obama and Santorum, seem to have unlearned many of the lessons of modern economics.

The 1984 Hatch-Waxman Act created a streamlined path for generic drugs to reach the market after pioneer drug patents expire. The result has been the most vigorous and competitive generic drug market in the world, but the Hatch-Waxman Act does not apply to most biologics. Isolated from a variety of...

Several recent books have criticized the pharmaceutical industry for developing too many "follow-on" or "me-too" drugs--a name given to drugs that work the same way as pioneering drugs that create a new class of treatments. Do follow-on drugs raise costs while diverting R&D funds from true innovation, and should the...